<?xml version="1.0" encoding="UTF-8"?>
<p>Owing to its inappropriate use, antifungal drug resistance has emerged as a major challenge that needs immediate attention. This is further aggravated because of the overuse of antibiotics, which affects the normal microflora of humans, providing a favorable environment for 
 <italic>C. albican</italic> to grow (
 <xref rid="B13" ref-type="bibr">Ben-Ami et al., 2012</xref>). Currently, available drugs are categorized into four major classes which include azoles, polyenes, pyrimidine analogs, and echinocandins. The primary targets of these antifungal drugs are the biosynthetic pathway of ergosterol, the cell wall of fungal cells, or the DNA/RNA of fungi (
 <xref rid="B19" ref-type="bibr">Borghi et al., 2016</xref>; 
 <xref rid="B142" ref-type="bibr">Sagatova et al., 2016</xref>; 
 <xref rid="B152" ref-type="bibr">Silva et al., 2017</xref>; 
 <xref ref-type="fig" rid="F1">Figure 1</xref>).
</p>
